# Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy

> **NCT00437476** · PHASE3 · UNKNOWN · sponsor: **IRCCS San Raffaele** · enrollment: 60 (estimated)

## Conditions studied

- HIV Infections
- Hepatitis C

## Interventions

- **DRUG:** LPV/r
- **DRUG:** Nucleoside Reverse Transcriptase Inhibitors
- **DRUG:** PEG-IFNa 2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00437476
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-02
- **Primary completion:** 2010-07
- **Final completion:** 2010-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2009-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437476, "Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00437476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*